News
In the first quarter of 2025, Dynavax reported record net HEPLISAV-B sales, showing a 36% increase compared to the same period in 2024. The company’s total market share in the U.S. hepatitis B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback